lifestyle.fictiontalk.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
OSE Immunotherapeutics
OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting
April 15, 2026
OSE Immunotherapeutics Evolves its Leadership Team
April 14, 2026
OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth
March 10, 2026
OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi®
March 2, 2026
OSE Immunotherapeutics sélectionne la pouchite chronique et l’hidradénite suppurée comme nouvelles indications clés pour Lusvertikimab
February 7, 2026
OSE Immunotherapeutics salue l’octroi de la désignation de médicament orphelin par la FDA du pegrizprument (VEL-101)
January 21, 2026